Winway Health Desk
DOJ sues CVS subsidiary for prescription drug fraud
The U.S. Department of Justice filed suit against Omnicare on Tuesday, claiming that the pharmacy services provider fraudulently billed Medicare, Medicaid and Tricare for...
AZ, Merck’s Lynparza narrowly snags FDA panel backing in pancreatic cancer
AstraZeneca and Merck’s Lynparza is looking to become the first in its class of PARP inhibitors to break into the pancreatic cancer market. And...
Accenture acquires AI consultancy Clarity Insights
Accenture will acquire Clarity Insights, a Chicago-based company that provides AI and machine learning services to companies in the healthcare, financial services and insurance...
SLIDESHOW: 2019 HCD Forum
Amid the rolling hills and verdant landscape of The Biltmore Estate in Asheville, N.C., Healthcare Design held its fourth annual HCD Forum Sept. 4-6....
All hail drug reps: Most cancer docs rely on pharma salespeople...
Here's a stat drugmakers would love to tout: With the cancer drug market exploding, oncologists rely on pharma's own sales reps for information about...
Velano Vascular reels in $25M to keep building blood-draw business
Velano Vascular has closed on $25 million in funding that will help the company advance its goal of transforming how blood is drawn from...
Furtive whispers and a bidding war: Inside Astellas’ $3B buyout of...
When Astellas earlier this month unveiled a $3 billion Audentes buyout, it touted the biotech's gene therapy candidates as a fifth pillar of its future...
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
GENEVA—Since unveiling its Tecentriq monotherapy win in previously untreated non-small lung cancer, Roche has faced criticism that the diagnostic test it used to identify trial...
Roche completes acquisition of Spark Therapeutics as regulators give go-ahead
Roche’s headquarters in Basel, Switzerland
Regulators have finally given Roche the green light to complete its acquisition of gene therapy developer Spark Therapeutics.
The Basel, Switzerland-based...
Chuffed on new launches, Eli Lilly unveils Street-beating 2020 sales forecast
Eli Lilly figures things are looking way up. With cost cuts and patent-cliff blows in the rearview mirror—and thanks to some outperforming new launches—the...
